These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 26134836)

  • 1. Comparison of Subcutaneous Regular Insulin and Lispro Insulin in Diabetics Receiving Continuous Nutrition: A Numerical Study.
    Stull MC; Strilka RJ; Clemens MS; Armen SB
    J Diabetes Sci Technol; 2015 Jun; 10(1):137-44. PubMed ID: 26134836
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Qualitative analysis of subcutaneous Lispro and regular insulin injections for stress hyperglycemia: a pilot numerical study.
    Strilka RJ; Armen SB; Indeck MC
    J Theor Biol; 2014 Sep; 356():192-200. PubMed ID: 24769252
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Simulation and qualitative analysis of glucose variability, mean glucose, and hypoglycemia after subcutaneous insulin therapy for stress hyperglycemia.
    Strilka RJ; Stull MC; Clemens MS; McCaver SC; Armen SB
    Theor Biol Med Model; 2016 Jan; 13():3. PubMed ID: 26819233
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insulin lispro: its role in the treatment of diabetes mellitus.
    Campbell RK; Campbell LK; White JR
    Ann Pharmacother; 1996 Nov; 30(11):1263-71. PubMed ID: 8913409
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of 70/30 biphasic insulin with glargine/lispro regimen in non-critically ill diabetic patients on continuous enteral nutrition therapy.
    Hsia E; Seggelke SA; Gibbs J; Rasouli N; Draznin B
    Nutr Clin Pract; 2011 Dec; 26(6):714-7. PubMed ID: 22205560
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved postprandial glycemic control in patients with type 2 diabetes from subcutaneous injection of insulin lispro with hyaluronidase.
    Hompesch M; Muchmore DB; Morrow L; Ludington E; Vaughn DE
    Diabetes Technol Ther; 2012 Mar; 14(3):218-24. PubMed ID: 22136324
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Subcutaneous injection of hyaluronidase with recombinant human insulin compared with insulin lispro in type 1 diabetes.
    Garg SK; Buse JB; Skyler JS; Vaughn DE; Muchmore DB
    Diabetes Obes Metab; 2014 Nov; 16(11):1065-9. PubMed ID: 24840317
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insulin lispro: a review of its pharmacological properties and therapeutic use in the management of diabetes mellitus.
    Wilde MI; McTavish D
    Drugs; 1997 Oct; 54(4):597-614. PubMed ID: 9339963
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of subcutaneous insulin lispro versus continuous intravenous regular insulin for the treatment of patients with diabetic ketoacidosis.
    Umpierrez GE; Latif K; Stoever J; Cuervo R; Park L; Freire AX; E Kitabchi A
    Am J Med; 2004 Sep; 117(5):291-6. PubMed ID: 15336577
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prolonged efficacy of short acting insulin Lispro in combination with human ultralente in insulin-dependent diabetes mellitus.
    Burge MR; Waters DL; Holcombe JH; Schade DS
    J Clin Endocrinol Metab; 1997 Mar; 82(3):920-4. PubMed ID: 9062507
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of human regular and lispro insulins after interruption of continuous subcutaneous insulin infusion and in the treatment of acutely decompensated IDDM.
    Attia N; Jones TW; Holcombe J; Tamborlane WV
    Diabetes Care; 1998 May; 21(5):817-21. PubMed ID: 9589247
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Meal composition is a determinant of lispro-induced hypoglycemia in IDDM.
    Burge MR; Castillo KR; Schade DS
    Diabetes Care; 1997 Feb; 20(2):152-5. PubMed ID: 9118763
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Humalog Mix 25 in patients with type 2 diabetes which do not achieve acceptable glycemic control with oral agents: results from a phase III, randomized, parallel study.
    Tîrgovişte CI; Străchinariu R; Farcaşiu E; Milicevic Z; Teodorescu G
    Rom J Intern Med; 2003; 41(2):153-62. PubMed ID: 15526500
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Subcutaneous use of a fast-acting insulin analog: an alternative treatment for pediatric patients with diabetic ketoacidosis.
    Della Manna T; Steinmetz L; Campos PR; Farhat SC; Schvartsman C; Kuperman H; Setian N; Damiani D
    Diabetes Care; 2005 Aug; 28(8):1856-61. PubMed ID: 16043723
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fields of application of continuous subcutaneous insulin infusion in the treatment of diabetes and implications in the use of rapid-acting insulin analogues.
    Pitocco D; Rizzi A; Scavone G; Tanese L; Zaccardi F; Manto A; Ghirlanda G
    Minerva Endocrinol; 2013 Sep; 38(3):321-8. PubMed ID: 24126552
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glucose profiles in a type 1 diabetic patient successively treated with CSII using regular insulin, lispro and an implantable insulin pump.
    Catargi B; Breilh D; Roger P; Tabarin A
    Diabetes Metab; 2000 May; 26(3):210-4. PubMed ID: 10880895
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glycemic control after 6 days of insulin pump reservoir use in type 1 diabetes: results of double-blind and open-label cross-over trials of insulin lispro and insulin aspart.
    Tamborlane WV; Renard E; Wadwa RP; Blevins T; Jacober SJ; Liu R; D'Souza DN; Rees TM
    J Diabetes; 2015 Mar; 7(2):270-8. PubMed ID: 24734891
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Restoration of early rise in plasma insulin levels improves the glucose tolerance of type 2 diabetic patients.
    Bruttomesso D; Pianta A; Mari A; Valerio A; Marescotti MC; Avogaro A; Tiengo A; Del Prato S
    Diabetes; 1999 Jan; 48(1):99-105. PubMed ID: 9892228
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison of lispro and regular insulin for the management of type 1 and type 2 diabetes in pregnancy.
    Durnwald CP; Landon MB
    J Matern Fetal Neonatal Med; 2008 May; 21(5):309-13. PubMed ID: 18446657
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Insulin glulisine, a new rapid-acting insulin analogue, displays a rapid time-action profile in obese non-diabetic subjects.
    Becker RH; Frick AD; Burger F; Potgieter JH; Scholtz H
    Exp Clin Endocrinol Diabetes; 2005 Sep; 113(8):435-43. PubMed ID: 16151977
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.